Bonjour,
Le projet suivant correspond à vos critères d'investissement
------------------------------------------------------------
SOURCE: UK Angel Investment Network
TITLE: Unique, cost effective product to prevent contraction of fatal hospital infections.
SYNOPSIS:
A unique polymer coating that prevents Urinary Tract Infections and bacterial colonization on medical devices. Management has already received £250k of non-dilutive grant funding. Very experienced team.
PROPOSAL SUMMARY:
Problem: In the United States, Catheter Acquired Urinary Tract Infections (CAUTI) account for over 13,000 deaths at a cost of $500m a year, a burden estimated to be $2bn worldwide. In the UK over 500,000 in-patients will fall victim to CAUTI which costs the NHS £100m a year in additional treatment and delayed discharge, 10 times the cost of the catheters themselves.
The Product : CamStent has developed a unique and cost-effective product for preventing CAUTI. The company’s proprietary polymer coating prevents the colonization of medical device surfaces by toxic micro-organisms. Unable to form active biofilms, the organisms fail to cause infections. The polymer is inert, neither drug nor biologic, and has a simple and expedited path to market release. The first product can be applied to silicone and silastic surfaces, particularly long-term Foley catheters. The coating is applied as a late step in the manufacture of commercial catheters, after the hollow tube has been fabricated but before sterilization and packaging.
This core technology is a platform for further applications to broadly prevent hospital acquired infections that cost the NHS over £1 billion/year. The Department of Health has instituted guidelines for controlling hospital acquired infections, seeking a 30% reduction in the number of cases and refusing reimbursement where poor protocols are at fault. CamStent’s coating can be applied to other silicon-based medical consumables (e.g. stents and drains), opening markets worth £1 billion. Subsequent variations of the core polymer will allow it to be anchored to surgical stainless steel for orthopaedic and other implant uses.
Competition: Foley catheters are the most common source of infection, accounting for 38% of cases. The worldwide market is £375 million/year, growing as the population ages. Antimicrobial catheters are reimbursed at £12 each as compared to £3 for uncoated products, but currently hold a small share in the overall market because clinical trials have not shown them to be effective at preventing infection.
Future: CamStent intends to license its coating formulation to a commercial manufacturer or specialty coating company for worldwide commercialization, anticipated within two years. Revenues are likely to include upfront payments, milestones payments on regulatory approval (e.g. CE Mark, FDA) and royalty payments on all sales. CamStent is seeking an exit value premarket of £20m or £50m in 5 years.
MANAGEMENT TEAM:
Dr David Hampton (CEO):
Former director at Medtronic, a global expert in medical device innovation with a track record of developing commercially successful medical devices and systems.
Clare Twemlow (CFO):
PwC qualified Chartered Accountant with senior management experience in high growth medical technology companies.
Dr Raman Minhas (BD):
Healthcare business and corporate development. Advised on transactions totalling over $30 m in realised value. UK qualified medical doctor.
Board:
Experienced Board including Toby Wilson Waterworth (Chairman) extensive experience in developing and funding healthcare related businesses, Richard Milne (NED) from London Business Angels and Director, Petrofac Group PLC, and Paul White (NED), ex CEO of Barts and The London NHS Trust and BT Healthcare.
RETURN ON INVESTMENT:
Looking to raise £400,000 for 17% of the company (of which £200k has been subscribed via pre-emption rights).
PROJECTED FINANCIAL INFORMATION:
Year Turnover Operating Profit
Year 1 0 EUR (£0) 0 EUR (-£392,000)
Year 2 0 EUR (£0) 0 EUR (-£710,000)
Year 3 2,075,670 EUR (£1,739,000)2,075,670 EUR (£1,656,000)
CAPITAL NEEDED: 477,440 EUR (£400,000)
MINIMUM INVESTMENT: 23,872 EUR (£20,000)
REGION: South East
INDUSTRY 1: Medical, Pharmaceuticals & Health Care
INDUSTRY 2: Products & Inventions
INVESTOR ROLE: Silent
BUSINESS STAGE: Pre-Startup/R&D
INVESTMENT REASON: Research & Development
POSTED: February 15, 2012
------------------------------------------------------------
Pour demander plus de renseignements sur le projet de l'entrepreneur, veuillez ouvrir session à
http://www.reseaufinancierfrancais.com/outils_investisseur?op=ip1&pid=ddf3fd6846c5e92f545342fa4f83521e, cliquer sur l'onglet "Contact" et puis sur le bouton "Contacter l'entrepreneur".
Si vous voulez modifier vos critères d’investissement veuillez ouvrir session à
www.reseaufinancierfrancais.com/outils_investisseur/35.Meilleures salutations,
Mike Lebus
Réseau Financier Français
www.reseaufinancierfrancais.com"Un lien privilégié entre les Entrepreneurs et les Business Angels"
The content of this promotion has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this promotion for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
This communication is made available in the United Kingdom to Retail Clients, Professional Clients and Eligible Counterparties as defined by the FSA and to persons falling within the "Financial Services and markets Act 2000". Persons who have received this communication should not rely upon it alone, and should seek professional advice if necessary.